Pro - Inflammatory cytokines, lymphocyte subsets and intravenous immunoglobulin therapy in guillain-barré syndrome

Turkish Journal of Pediatrics

Volumn 40, Issue 3, 1998, Pages 357-363

  Tekgül, Hasan ^a   Kütükçüler, Necil ^a   Çaǧlayan, Suat ^a   Tütüncüoǧlu, Sarenur ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Cellular immunity; Cytokines; Guillain barr ; Intravenous immunoglobulin; Lymphocyte subsets; Syndrome

Indexed keywords

HLA DR ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ARTICLE; BLOOD LEVEL; CELLULAR IMMUNITY; CEREBROSPINAL FLUID LEVEL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; MALE; T LYMPHOCYTE SUBPOPULATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOCYTE SUBSETS; MALE; POLYRADICULONEUROPATHY;

EID: 0031690008     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome-Part I. Muscle Nerve 1995; 18: 137-153.
2. Winer JB, Gray IA, Gregson NA, et al. A prospective study of acute idiopathic neuropathy. III. Immunological studies. J Neurol Neurosurg Psychiatry 1988; 51: 619-625.
3. Hartung HP, Heininger K, Schäfer B, Fierz W, Toyka KV. Immune mechanism in inflammatory polyneuropathy. Ann NY Acad Sci 1988; 540: 122-161.
4. Hartung HP, Jung S, Stoll G, et al. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J Neuroimmunol 1992; 40: 197-210.
5. Selmaj K, Xeman A, McLean BN, Thompson EJ. Tumor necrosis factor mediates myelin and oligodendrocyte damages in vitro. Ann Neurol 1988; 23: 339-346.
6. Kleyweg RP, van der Meché FG, Meulstee J. Treatment of Guillain-Barré syndrome with high-dose gammaglobulin. Neurology 1988; 38: 1639-1641.
7. Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administered immune serum globulin in patients with Guillain-Barré syndrome. J Pediatr 1990; 116: 141-144.
8. Baskin E, Türkay S, Içaǧasioǧlu D, Tanzer F, Cevit Ö. High-dose intravenous immune globulin in the management of severe Guillain-Barré syndrome. Turk J Pediatr 1996; 38: 119-123.
9. NINCDS Committee. Criteria for Guillain-Barré syndrome. Ann Neurol 1978; 3: 565-566.
10. Iqbal A, Oger JJ, Arnason BG. Cell-mediated immunity in idiopathic polyneuritis. Ann Neurol 1981; 9: 65-69.
11. Hartung HP, Hughes RA, Taylor WA, Heininger K, Reiners K, Toyka KV. T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-α receptors. Neurology 1990; 40: 215-218.
12. Cornblath DR, Griffin DE, Welch D, Griffin JW, McArthur JC. Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J Neuroimmunol 1990; 26: 113-118.
13. Taylor WA, Hughes RA. T lymphocyte activation antigens in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1989; 24: 33-39.
14. Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991; 30: 48-53.
15. Sharief MK, McLean B, Thompson EJ. Elevated serum levels of tumor necrosis factor-alpha in Guillain-Barré syndrome. Ann Neurol 1993; 33: 591-596.
16. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rehumatic diseases. Arthritis Rheum 1992; 35: 1160-1169.
17. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part II. Muscle Nerve 1995; 18: 137-153.